The tuberculosis vaccine candidate M72/AS01E, which contains 2 Mycobacterium tuberculosis proteins, provided 54.0% protection against active pulmonary tuberculosis in adults infected with latent tuberculosis infection, according to the results of a phase 2b trial reported in the New England Journal of Medicine.
The 3573 participants who tested negative for HIV in Kenya, South Africa, and Zambia were randomly assigned to receive 2 doses of either M72/AS01E or placebo 1 month apart. Most participants had previously received the bacille Calmette–Guérin vaccine.
Slomski A. Vaccine Prevents Active Tuberculosis. JAMA. 2018;320(20):2068. doi:10.1001/jama.2018.17808
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: